POLISCOPE
Back to feed
Part ofHealthcare →
SB 1224CALIFORNIASession 20252026
High Impact

California creates research fund and partnership for emerging therapies clinical trials

Original title: The California Emerging Therapies Research Partnership Act.

August 13, 2026

HealthcareResearchVeterans AffairsControlled SubstancesClinical TrialsState FundingTheCaliforniaEmergingTherapiesResearchPartnershipAct

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

This bill creates a new state-managed funding mechanism for clinical research into substances currently classified as Schedule I, potentially impacting how California coordinates with federal health agencies to study emerging therapies for veterans.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Veterans

The bill establishes an advisory council specifically to research emerging therapies for veterans.

University of California

The university is designated to serve as an anchor institution for clinical trials and must participate in readiness certification activities.

What changed

Last recorded activity August 13, 2026.

What's next

Introduced.

Summary

SB 1224 establishes the California Emerging Therapies Research Partnership Fund to support federally registered clinical trials for substances including psilocybin, ibogaine, and MDMA. The bill mandates state agencies to apply for federal partnership designation with the Advanced Research Projects Agency for Health () and creates an advisory council to oversee research for veterans and priority populations.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Why It Matters

This bill creates a new state-managed funding mechanism for clinical research into substances currently classified as Schedule I, potentially impacting how California coordinates with federal health agencies to study emerging therapies for veterans.

Frequently Asked Questions

Will this bill allow the state to buy or distribute drugs like psilocybin?
No, the bill explicitly prohibits the use of fund money for purchasing, distributing, or administering controlled substances.
What is the purpose of the new research fund?
The fund is intended to issue grants to University of California campuses to serve as anchor institutions for federally registered clinical trials involving emerging therapies.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

State-Federal Research Alignment

The bill demonstrates a shift toward leveraging federal ARPA-H partnerships to conduct clinical research on substances that remain federally restricted.

Advanced Research Projects Agency for HealthCalifornia Health and Human Services Agency

Connected Entities

organizationCalifornia Health and Human Services Agency“Responsible for submitting the federal partnership application.”Map →
organizationCalifornia Emerging Therapies Research Partnership Fund“A new fund created within the State Treasury to support clinical trial research.”Map →
organizationCalifornia Veteran Emerging Therapies Research Advisory Council“New advisory body for research on veterans and priority populations.”Map →
organizationDepartment of Veterans Affairs“Co-administrator of the new research fund and convener of the advisory council.”Map →
organizationState Department of Health Care Services“Co-administrator of the new research fund.”Map →
organizationUniversity of California“Designated as the anchor institution for clinical trials.”Map →
organizationAdvanced Research Projects Agency for Health“Federal agency to which California will apply for partnership designation.”Map →

Sources

Open source document

openstates.org

Analysis Score

0–100
  • Significance75
    How much this matters to a regular citizen
  • Controversy60
    Intensity of disagreement among stakeholders
  • Entertainment20
    Compellingness for a non-policy-wonk reader
  • Buzz40
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record